Edwards Lifesciences Corp Overview
Industry: Medical Devices
Sector: Healthcare
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California. Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of hea Read MoreMavefund brings filings, fundamentals, valuation, price history and news for Edwards Lifesciences Corp into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Net sales was $1.7B (+14% YoY); EPS was $2.95 (reported).
Net sales
$1.7B
+14% YoY
EPS
$2.95
reported
Operating income
-$21.3M
-15% YoY
Net income
$241.4M
-27% YoY
What changed
- Net sales +14% YoY to $1.7B; EPS reported to $2.95.
- Operating income -15% YoY to -$21.3M.
- Net income -27% YoY to $241.4M.
Guidance / outlook
The company expects the value of its growing body of clinical evidence will further increase with time, as demonstrated by recent reductions in all-cause mortality and heart failure hospitalizations, and will support continued physician adoption and expansion of access for patients with tricuspid regurgitation.
Earnings release
Open filing
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
SEC filing
10-Q
Aug 04, 2026
SEC filing
8-K
Jul 23, 2026
SEC filing
10-Q
May 06, 2026
SEC filing
8-K
Apr 23, 2026
Earnings release
Earnings release
Apr 23, 2026
SEC filing
10-K
Feb 25, 2026
SEC filing
8-K
Feb 10, 2026
Earnings release
Earnings release
Feb 10, 2026
SEC filing
10-Q
Nov 05, 2025
SEC filing
8-K
Oct 30, 2025
Earnings release
Earnings release
Oct 30, 2025
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
Edwards Lifesciences Corp. stock underperforms Friday when compared to competitors
Headline from MarketWatch: Edwards Lifesciences Corp. stock underperforms Friday when compared to competitors.
Edwards Lifesciences Corp. stock underperforms Friday when compared to competitors
Headline from marketwatch.com: Edwards Lifesciences Corp. stock underperforms Friday when compared to competitors.
Edwards Lifesciences: Strong Execution, But Little Room For Error At $90 (NYSE:EW)
Headline from Seeking Alpha: Edwards Lifesciences: Strong Execution, But Little Room For Error At $90 (NYSE:EW).
Edwards Lifesciences CVP sells $56,966 in company stock By Investing.com
Headline from Investing.com Nigeria: Edwards Lifesciences CVP sells $56,966 in company stock By Investing.com.
Edwards Lifesciences CVP sells $56,966 in company stock By Investing.com
Headline from Investing.com South Africa: Edwards Lifesciences CVP sells $56,966 in company stock By Investing.com.
Edwards Lifesciences CVP sells $56,966 in company stock
Headline from Investing.com: Edwards Lifesciences CVP sells $56,966 in company stock.
Earnings Per Share
Score 3.00/5
Edwards Lifesciences Corp boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
In
Medical Devices industry
, Abbott Laboratories
, DexCom Inc
, Iradimed Co
are companies with high ratings.
Return on Equity
Score 2.61/5
Edwards Lifesciences Corp stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Score 3.94/5
Edwards Lifesciences Corp
commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Score 2.81/5
Edwards Lifesciences Corp
attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
, also exhibit high scores.
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Verified SEC statements load when this section enters view.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.
Financial Ratio
Yearly
Quarterly
Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios